[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipids\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipids":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100629762","impact-of-the-corrie-lipids-digital-health-program-on-lipid-optimization-100629762",false,"NCT07478887","Impact of the Corrie Lipids Digital Health Program on Lipid Optimization","Corrie Lipids Program: Optimizing LDL-Cholesterol by Improving Awareness, Access, and Achievement","Inclusion Criteria:\n\n* Age ≥18 years\n* Uncontrolled LDL-C per AHA\u002FACC guidelines\n* At least 1 major cardiovascular risk factor, including: high risk for ASCVD (individuals who meet criteria for Lipid-Lowering Therapy (LLT) based on ASCVD risk assessment using the most up-to-date guidelines), known ASCVD or subclinical ASCVD based on imaging, clinically diagnosed familial hypercholesterolemia or LDL-C ≥190 mg\u002FdL, diabetes mellitus, history of statin-associated side effects\n* Has a primary care physician and\u002For cardiologist who can prescribe lipid therapy\n* Owns a smartphone and agrees to the End User License Agreement to use the digital health app\n* Provided informed consent before initiation of study-specific activities\n\nExclusion Criteria:\n\n* Motor, cognitive, auditory, or visual impairment limiting technology use\n* Does not speak English\n* Malignancy (except nonmelanoma skin cancers or cervical or breast ductal carcinoma in situ within the previous 5 years)\n* Pregnancy (positive pregnancy test, highly sensitive urine or serum), plan to become pregnant or donate eggs, breastfeeding or plan to breastfeed\n* Likely to not be available to comply with all required study procedures to the best of the patient's and investigator's knowledge\n* History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","INTERVENTIONAL",[23],"NA","The overall objective is to evaluate the effectiveness and implementation of the Corrie Lipids Program, a comprehensive digital health initiative designed to address critical gaps in lipid-lowering as a component of ASCVD treatment by delivering an intervention that combines a patient-facing smartphone app, clinician education and coaching, and seamless incorporation into clinical workflows.\n\nResearchers plan to assess this multicenter digital health initiative in approximately 1,000 adults with uncontrolled LDL-C and elevated ASCVD risk using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. The study will examine whether the program improves LDL-C goal attainment, app engagement, prescribing patterns, and LDL-C monitoring, while also identifying barriers and facilitators to implementation across sites.",[26,27,28,29,30],"Cardiovascular Risk","LDL-C","Lipids","Digital Health","Implementation Science",[32,33],"Apolipoprotein B (apoB)","Lipoprotein-a (Lp(a)","RECRUITING","2026-03-13",{"date":37,"type":38},"2026-03-18","ACTUAL",{"date":40,"type":38},"2025-06-20",{"date":42,"type":20},"2027-12",{"name":44,"class":45},"Johns Hopkins University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100626803","phase-3-triple-oral-therapy-with-bempedoic-acid-vs-usual-care-in-early-lipid-management-of-patients-with-acute-coronary-syndrome-100626803","NCT07440381","triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE","triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (PERSUADE) Trial","PERSUADE","Inclusion Criteria:\n\n* Age ≥18 years\n* Male and females at birth\n* Admitted for ACS caused by an atherothrombotic coronary event;\n* Calculated LDL-c: 70-140 mg\u002FdL within 24 hours from admission for the ACS index event\n* Lipid lowering therapy on admission consisting of a low\u002Fmoderate intensity statin or a high intensity statin (HIS); or no lipid lowering therapy (naïve patients)\n* Lipid-lowering therapy at discharge (at the time of randomization) consisting of HIS or HIS + ezetimibe\n* Scheduled home discharge\n* Written informed consent provided; patients who are unable to give informed consent for any reason will be excluded from the study.\n\nExclusion Criteria:\n\n* Patients already treated with HIS+Ezetimibe on admission for the ACS event,\n* Patients currently, previously or planned to be treated with PCSK9i or inclisiran,\n* Patients treated currently or in the last 3 months with bempedoic acid or in whom this treatment is planned in the following 8 weeks,\n* Known allergy, sensitivity or intolerance to bempedoic acid and\u002For study drugs' formulation ingredients (e.g. lactose intolerance),\n* Patients with history of documented intolerance to statins, ezetimibe or bempedoic acid\n* Patients with known Familial Hypercholesterolemia (FH; heterozygous or homozygous),\n* Patients with plasma triglycerides concentration exceeding 400 mg\u002FdL (4.52 mmol\u002FL),\n* Patients with dysbetalipoproteinemia (type III hyperlipoproteinemia),\n* Unstable clinical status (hemodynamic or electrical instability),\n* Severe renal dysfunction (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2 using the CKD-EPI formula),\n* Active liver disease or hepatic dysfunction (AST or ALT levels \\> 3xUNL),\n* Current enrolment in another investigational device or drug study,\n* Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception,\n* Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.",{"count":56,"type":20},600,[58],"PHASE3","Early and intensive LDL-cholesterol (LDL-c) reduction is associated with improved short-term and long-term outcomes. Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers LDL-c upstream of HMG-CoA reductase. When added to maximally tolerated statins, it has demonstrated significant LDL-c reduction and cardiovascular benefit, particularly in statin-intolerant or high-risk patients. However, evidence on early initiation of bempedoic acid during the index ACS hospitalization is currently lacking. The investigators therefore would like to see whether early (pre-discharge) initiation of an oral triple lipid-lowering therapy including bempedoic acid, high-intensity statin (HIS), and ezetimibe is superior to usual care in reducing LDL-c levels at 8 weeks after randomization in patients hospitalized for ACS.",[61,62,28],"Acute Coronary Syndromes","Secondary Prevention",[64,65,66,67,68],"ACS","Lipid-lowering therapy","atherothrombotic coronary event","secondary prevention","triple oral lipid lowering therapy","NOT_YET_RECRUITING","2026-02-26",{"date":72,"type":38},"2026-02-27",{"date":74,"type":20},"2026-09",{"date":76,"type":20},"2027-08",{"name":78,"class":45},"Heart Care Foundation",35,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100618398","resolving-inflammation-through-diet-for-health-resolvin-100618398","NCT07331103","RESOLving INflammation Through Diet for Health (RESOLVIN)","RESOLving INflammation Through Diet for Health Multicenter, Prospective Randomized, Controlled and Open- Label to Examine the Impact of a Diet Enriched in Omega 3 Fatty Acids of Animal and Vegetal Origin on Circulating Lipid-driven Pro-\u002FAntiinflammatory Balance in Subjects at Moderate to High Cardiovascular Risk.","RESOLving","Inclusion Criteria:\n\n* Participants are subjects \\>55 y old from both sexes (\\>=40% women) with moderate to high cardiovascular risk (ANNEX 1: SCORE2, SCORE2-OP and SCORE2-Diabetes assessment).\n\nExclusion Criteria:\n\n* cardiovascular disease,\n* established atherosclerotic vascular disease involving the coronary, peripheral, carotid, or aortic territories (identified by computerized tomography (CT) of coronary arteries, MRI, carotid or peripheral ultrasound imaging),\n* chronic treatment with n-3 PUFA containing products (i.e., Vazkepa),\n* a condition that interferes with the possibility to follow the dietary intervention, such as fish allergy or being a vegan,\n* significant liver dysfunction,\n* participation in another intervention clinical study.","55 Years",{"count":90,"type":20},324,[23],"Hyperlipidemia is the main driver of atherosclerotic cardiovascular disease (ASCVD), both through direct effects and as trigger of the chronic inflammation behind a cardiovascular health-to-disease transition. While lipid-lowering is an effective way to reduce the ASCVD risk, the residual risk remains high. In addition, a substantial proportion of ASCVD events occur in the absence of overt hyperlipidemia. Several lines of evidence ranging from experimental models to population studies and interventional clinical trials support chronic inflammation as the causal residual risk of CVD. The CVD risk-associated lipid classes contain fatty acids that can be liberated and metabolized into both inflammation-promoting as well as inflammation-resolving drivers, providing the rationale for focusing on this balance in the present project. Above all, the omega-3 fatty acid class can resolve inflammation but the potential impact is currently largely underestimated in CVD preventive recommendations. As cardiovascular preventive measures ease the burden placed on the individual, population, and on the health care system, it is critical to raise public awareness for chronic inflammation as a causative and modifiable cardiovascular risk factor and to provide tools for how to control and monitor it. As an alternative to marine sources, principally eicosapentaenoic acid (EPA) and less docosahexaenoic acid (DHA) can be endogenously produced from alpha-linolenic acid (ALA) found in plant oils. Secondarily the possibility to increase the consumption of vegetable oil may possibly decrease the environmental impacts of an intensive fishing and consecutive marine system imbalance. The overarching objective of CARE-IN-HEALTH is to assess if PUFAs may contribute to the resolution of the chronic lipid-driven\u002F-regulated vascular inflammation in order to develop and test, in a real-life setting, tools for use in health care and by citizens to stay healthy by an adequate resolution of the chronic inflammation. The primary objective of the present study is to compare the effect on a lipid\u002Finflammation-derived risk score of diets supplemented with polyunsaturated fatty acids (PUFA) of animal or vegetal origin with a nonenriched diet. The secondary objectives are a) to assess the acceptance of supplementation of diet with animal-derived or plant-derived PUFAs; b) to improve circulating lipid, inflammatory glycemic profile based on serial measurements of circulating biomarkers by means of PUFA supplementation. The study aims to identify a blueprint for how to control lipid-driven chronic inflammation by simple dietary interventions. Study population Participants to be considered for eligibility in the trial are adults aged \\>55 y, of both sexes (\\>=40% women), at moderate to high cardiovascular risk. The inclusion criteria are: Eligible participants will be at moderate to high SCORE2, SCORE2-OP and SCORE2-Diabetes risk level.\n\nNon-eligible subjects will be those with:\n\n* cardiovascular disease,\n* established atherosclerotic vascular disease involving the coronary, peripheral, carotid, or aortic territories (identified by computerized tomography (CT) of coronary arteries, MRI, carotid or peripheral ultrasound imaging),\n* chronic treatment with n-3 PUFA containing products (i.e., Vazkepa) or fibrates,\n* a condition that interferes with the possibility to follow the dietary intervention, such as fish allergy or being a vegan,\n* significant liver dysfunction,\n* participation in another intervention clinical study. Participants will be centrally randomized by a web-based system to one of the 3 diets: 1) supplementation with 4 grams n-3 PUFAs (containing 2262.5 mg DHA plus 1739.1 mg EPA), 2) diet enriched with n-3 PUFAs of vegetable origin (Camelina Sativa Oil) + vitamin E 24 mg, and 3) regular uncontrolled diet + vitamin E 24 mg. The daily intake of 10 grams of ALA for participants randomized to Camelina Sativa Oil is equivalent to approximately 1500 mg of n-3 PUFAs. Fish oil and Camelina Sativa oil will be administered as liquid oils for the duration of 12 weeks. The addition of vitamin E is aimed at supplementing the same amount of this vitamin to participants. Eligible participants will undergo a clinical visit when also a blood sample will be taken at baseline and at 12 weeks follow-up. The main analysis will be performed according to a per protocol approach, therefore only participants compliant with study treatments will be included in the analysis. Primary objective: to compare the effect on a lipid\u002Finflammation-derived risk score, based on circulating molecules, of diets enriched with PUFA of animal or vegetal origin with a non-enriched diet. Secondary objectives: a) to assess the acceptance of supplementation of diet with animal-derived or plant-derived PUFAs; b) to improve circulating lipidic\u002Fglycemic inflammatory profile. All 324 participants enrolled in the trial will have blood samples taken twice (at baseline and 12 weeks),",[94,28,95,96],"Cardiovascualr Disease","Inflammation","n-3 Polyunsatured Fatty Acids (n-3 PUFA)",[98,99,100,101,102,103,104],"ASCVD","n-3 polyunsatured fatty acids","lipid driven\u002Fregulated vascular inflammation","n-3 PUFA","DHA","EPA","ALA","2025-12-29",{"date":107,"type":38},"2026-01-09",{"date":109,"type":38},"2025-11-26",{"date":111,"type":20},"2026-06-30",{"name":113,"class":45},"Mario Negri Institute for Pharmacological Research",5]